<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20240725222950&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20240725222950&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 26 Jul 2024 02:29:50 +0000</lastbuilddate>
<pubDate>Wed, 24 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The Politics of HFpEF-What's Good for the Left Is Good for the Right</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39046754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 24. doi: 10.1001/jamacardio.2024.1925. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39046754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39046754</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1925>10.1001/jamacardio.2024.1925</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39046754</guid>
<pubDate>Wed, 24 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Gaurav Gulati</dc:creator>
<dc:creator>Sheldon E Litwin</dc:creator>
<dc:date>2024-07-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Politics of HFpEF-What's Good for the Left Is Good for the Right</dc:title>
<dc:identifier>pmid:39046754</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1925</dc:identifier>
</item>
<item>
<title>Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39046727/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial reveal that treatment with dapagliflozin for 24 weeks reduced pulsatile pulmonary vascular load and enhanced dynamic RV-PA interaction during exercise in patients with HFpEF, findings that are related to the magnitude of PCWP reduction. Benefits on dynamic right ventricular-pulmonary vascular coupling may partially explain the benefits of SGLT2 inhibitors in HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 24. doi: 10.1001/jamacardio.2024.1914. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Increases in pulmonary capillary wedge pressure (PCWP) during exercise reduce pulmonary artery (PA) compliance, increase pulsatile right ventricular (RV) afterload, and impair RV-PA coupling in patients with heart failure with preserved ejection fraction (HFpEF). The effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on pulmonary vascular properties and RV-PA coupling are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To test the effect of dapagliflozin on right ventricular performance and pulmonary vascular load during exertion in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA) randomized clinical trial demonstrated improvement in PCWP at rest and exercise over 24 weeks with dapagliflozin compared with placebo with participants recruited between February 2021 and May 2022. This secondary analysis evaluates the effects of dapagliflozin on pulsatile pulmonary vascular load and RV-PA coupling using simultaneous echocardiography and high-fidelity invasive hemodynamic testing with exercise. This was a single-center study including patients with hemodynamically confirmed HFpEF with exercise PCWP of 25 mm Hg or greater.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Dapagliflozin or placebo for 24 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Pulsatile pulmonary vascular load (PA compliance and elastance) and right ventricular performance (PA pulsatility index, RV systolic velocity [s']/PA mean) during rest and exercise.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 37 randomized participants (mean [SD] age, 67.4 [8.5] years; 25 female [65%]; mean [SD] body mass index, 34.9 [6.7]; calculated as weight in kilograms divided by height in meters squared), there was no effect of dapagliflozin on PA loading or RV-PA interaction at rest. However, with exercise, dapagliflozin improved PA compliance (placebo-corrected mean difference, 0.57 mL/mm Hg; 95% CI, 0.11-1.03 mL/mm Hg; P = .02) and decreased PA elastance (stiffness; -0.17 mm Hg/mL; 95% CI, -0.28 to -0.07 mm Hg/mL; P = .001). RV function during exercise improved, with increase in PA pulsatility index (0.33; 95% CI, 0.08-0.59; P = .01) and increase in exercise RV s' indexed to PA pressure (0.09 cm·s-1/mm Hg; 95% CI, 0.02-0.16 cm·s-1/mm Hg; P = .01). Improvements in pulsatile RV load and RV-PA coupling were correlated with reduction in right atrial (RA) pressure (PA elastance Pearson r = 0.55; P =.008; RV s'/PA elastance Pearson r = -0.60; P =.002) and PCWP (PA elastance Pearson r = 0.58; P &lt;.001; RV s'/PA elastance Pearson r = -0.47; P = .02). Dapagliflozin increased resistance-compliance time (dapagliflozin, median [IQR] change, 0.06 [0.03-0.15] seconds; placebo, median [IQR] change, 0.01 [-0.02 to 0.05] seconds; P =.046), resulting in higher PA compliance for any exercise pulmonary vascular resistance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial reveal that treatment with dapagliflozin for 24 weeks reduced pulsatile pulmonary vascular load and enhanced dynamic RV-PA interaction during exercise in patients with HFpEF, findings that are related to the magnitude of PCWP reduction. Benefits on dynamic right ventricular-pulmonary vascular coupling may partially explain the benefits of SGLT2 inhibitors in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04730947.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39046727/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39046727</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1914>10.1001/jamacardio.2024.1914</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39046727</guid>
<pubDate>Wed, 24 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yogesh N V Reddy</dc:creator>
<dc:creator>Rickey E Carter</dc:creator>
<dc:creator>Hidemi Sorimachi</dc:creator>
<dc:creator>Massar Omar</dc:creator>
<dc:creator>Dejana Popovic</dc:creator>
<dc:creator>Alessio Alogna</dc:creator>
<dc:creator>Michael D Jensen</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-07-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39046727</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1914</dc:identifier>
</item>
<item>
<title>Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39046724/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this analysis of a pragmatic RCT, claims and EHR data provided the most clinical end-point data when compared with participant-reported events. These findings provide a framework for collecting end points in pragmatic clinical trials. Further work is needed to understand the data source combinations that most effectively provide clinical end-point data in RCTs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 24. doi: 10.1001/jamacardio.2024.2019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Pragmatic randomized clinical trials (RCTs) often use multiple data sources to examine clinical events, but the relative contribution of data sources to clinical end-point rates is understudied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the contribution of data sources (electronic health records [EHRs], public/private insurance claims, and/or participant-reported data) to clinical end points among ADAPTABLE participants who had available data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The ADAPTABLE study was an open-label, pragmatic RCT from April 2016 through June 2019 conducted in research networks within clinical practice. Participants had existing atherosclerotic cardiovascular disease and available data to analyze. The characteristics of patients by combinations of data source availability were compared to examine the contribution of each of the data sources to end-point ascertainment. Data for this prespecified analysis were examined from January 2022 to June 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Randomized exposure to 81 mg or 325 mg of aspirin daily.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Number of events for the primary end point (composite of death, hospitalization for myocardial infarction, and hospitalization for stroke) that were contributed by EHR or claims data and then number of events contributed by each additional data source.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 15 006 participants randomized with at least 1 other source of data available beyond participant-reported data, there were 8756 (58.3%) with participant-reported and EHR data; 4291 (28.6%) with participant-reported, EHR, and claims data; 1412 (9.4%) with EHR-only data; 262 (1.7%) with participant-reported and claims data; 202 (1.3%) with EHR and claims data; and 83 (0.6%) with claims-only data. Participants with EHR-only data were younger (median age, 63.7 years; IQR, 55.8-71.4) compared with the other groups (range, 65.6-71.9 years). Among participants with both EHR and claims data, with or without participant-reported data (n = 4493), for each outcome, most events (92%-100%) were identified in the EHR or in claims data. For all clinical end points, participant-reported data contributed less than 10% of events not otherwise available from claims or EHR data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this analysis of a pragmatic RCT, claims and EHR data provided the most clinical end-point data when compared with participant-reported events. These findings provide a framework for collecting end points in pragmatic clinical trials. Further work is needed to understand the data source combinations that most effectively provide clinical end-point data in RCTs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39046724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39046724</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2019>10.1001/jamacardio.2024.2019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39046724</guid>
<pubDate>Wed, 24 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer A Rymer</dc:creator>
<dc:creator>Hillary Mulder</dc:creator>
<dc:creator>Lisa M Wruck</dc:creator>
<dc:creator>Daniel Muñoz</dc:creator>
<dc:creator>Sunil Kripalani</dc:creator>
<dc:creator>Mark B Effron</dc:creator>
<dc:creator>Kamal Gupta</dc:creator>
<dc:creator>Eileen Handberg</dc:creator>
<dc:creator>Sandeep Jain</dc:creator>
<dc:creator>Saket Girotra</dc:creator>
<dc:creator>Jeffrey Whittle</dc:creator>
<dc:creator>Rachel Hess</dc:creator>
<dc:creator>Catherine P Benziger</dc:creator>
<dc:creator>Kirk U Knowlton</dc:creator>
<dc:creator>Lesley H Curtis</dc:creator>
<dc:creator>Matthew T Roe</dc:creator>
<dc:creator>Bradley G Hammill</dc:creator>
<dc:creator>Russell L Rothman</dc:creator>
<dc:creator>Robert Harrington</dc:creator>
<dc:creator>Adrian Hernandez</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:date>2024-07-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39046724</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2019</dc:identifier>
</item>
<item>
<title>Noninvasive Visualization of the Atrioventricular Conduction System Using Cardiac Computed Tomography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39046719/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that CECT could accurately localize the fatty tissue that insulates the AVCS from surrounding atrial and ventricular myocardium and may enhance the efficacy and safety of procedures targeting the conduction system and structures in its proximity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 24. doi: 10.1001/jamacardio.2024.2012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Noninvasive localization of the compact atrioventricular node and the proximal specialized conduction system (AVCS) would enhance planning for transcatheter aortic valve and complex or congenital heart disease surgical procedures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To test the hypothesis that preprocedure contrast-enhanced cardiac computed tomography (CECT) can accurately localize the AVCS by identification of the fat that insulates the conductive myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prospective cohort study that took place at an academic tertiary care center. Included in the study were patients with CECT acquired less than 1 month before atrial fibrillation ablation and electroanatomic localization of the His electrogram signal on electroanatomic mapping (EAM) between January 2022 and January 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Preprocedure CECT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The distance from the His electrogram signal to the fat segmentation encompassing the AVCS on CECT, after registration of the images to EAM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 20 patients (mean [SD] age, 66 [10] years; 15 male [75%]) in the cohort, the mean (SD) attenuation of the AVCS fat segmentation was 2.9 (21.5) Hounsfield units. The mean (SD) distance from the His electrogram to the closest AVCS fat voxel was 3.3 (1.6) mm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that CECT could accurately localize the fatty tissue that insulates the AVCS from surrounding atrial and ventricular myocardium and may enhance the efficacy and safety of procedures targeting the conduction system and structures in its proximity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39046719/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39046719</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2012>10.1001/jamacardio.2024.2012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39046719</guid>
<pubDate>Wed, 24 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mirmilad Khoshknab</dc:creator>
<dc:creator>Tarek Zghaib</dc:creator>
<dc:creator>Lingyu Xu</dc:creator>
<dc:creator>Timothy Markman</dc:creator>
<dc:creator>Constantine Mavroudis</dc:creator>
<dc:creator>Benoit Desjardins</dc:creator>
<dc:creator>Saman Nazarian</dc:creator>
<dc:date>2024-07-24</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Noninvasive Visualization of the Atrioventricular Conduction System Using Cardiac Computed Tomography</dc:title>
<dc:identifier>pmid:39046719</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2012</dc:identifier>
</item>
<item>
<title>Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports: 2024 Update of the Utstein Out-of-Hospital Cardiac Arrest Registry Template</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39045706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>The Utstein Out-of-Hospital Cardiac Arrest Resuscitation Registry Template, introduced in 1991 and updated in 2004 and 2015, standardizes data collection to enable research, evaluation, and comparisons of systems of care. The impetus for the current update stemmed from significant advances in the field and insights from registry development and regional comparisons. This 2024 update involved representatives of the International Liaison Committee on Resuscitation and used a modified Delphi...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 24. doi: 10.1161/CIR.0000000000001243. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The Utstein Out-of-Hospital Cardiac Arrest Resuscitation Registry Template, introduced in 1991 and updated in 2004 and 2015, standardizes data collection to enable research, evaluation, and comparisons of systems of care. The impetus for the current update stemmed from significant advances in the field and insights from registry development and regional comparisons. This 2024 update involved representatives of the International Liaison Committee on Resuscitation and used a modified Delphi process. Every 2015 Utstein data element was reviewed for relevance, priority (core or supplemental), and improvement. New variables were proposed and refined. All changes were voted on for inclusion. The 2015 domains-system, dispatch, patient, process, and outcomes-were retained. Further clarity is provided for the definitions of out-of-hospital cardiac arrest attended resuscitation and attempted resuscitation. Changes reflect advancements in dispatch, early response systems, and resuscitation care, as well as the importance of prehospital outcomes. Time intervals such as emergency medical service response time now emphasize precise reporting of the times used. New flowcharts aid the reporting of system effectiveness for patients with an attempted resuscitation and system efficacy for the Utstein comparator group. Recognizing the varying capacities of emergency systems globally, the writing group provided a minimal dataset for settings with developing emergency medical systems. Supplementary variables are considered useful for research purposes. These revisions aim to elevate data collection and reporting transparency by registries and researchers and to advance international comparisons and collaborations. The overarching objective remains the improvement of outcomes for patients with out-of-hospital cardiac arrest.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39045706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39045706</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001243>10.1161/CIR.0000000000001243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39045706</guid>
<pubDate>Wed, 24 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Janet E Bray</dc:creator>
<dc:creator>Jan-Thorsten Grasner</dc:creator>
<dc:creator>Jerry P Nolan</dc:creator>
<dc:creator>Taku Iwami</dc:creator>
<dc:creator>Marcus E H Ong</dc:creator>
<dc:creator>Judith Finn</dc:creator>
<dc:creator>Bryan McNally</dc:creator>
<dc:creator>Ziad Nehme</dc:creator>
<dc:creator>Comilla Sasson</dc:creator>
<dc:creator>Janice Tijssen</dc:creator>
<dc:creator>Shir Lynn Lim</dc:creator>
<dc:creator>Ingvild Tjelmeland</dc:creator>
<dc:creator>Jan Wnent</dc:creator>
<dc:creator>Bridget Dicker</dc:creator>
<dc:creator>Chika Nishiyama</dc:creator>
<dc:creator>Zakary Doherty</dc:creator>
<dc:creator>Michelle Welsford</dc:creator>
<dc:creator>Gavin D Perkins</dc:creator>
<dc:creator>International Liaison Committee on Resuscitation</dc:creator>
<dc:date>2024-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports: 2024 Update of the Utstein Out-of-Hospital Cardiac Arrest Registry Template</dc:title>
<dc:identifier>pmid:39045706</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001243</dc:identifier>
</item>
<item>
<title>Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39045686/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: NFL reflects overt and covert episodes of cerebral ischemia and improves risk assessment of stroke and death in patients with AF without oral anticoagulation, including in patients without previous stroke. The combination of NFL with information on age, history of stroke, and other biomarkers should be explored as a future avenue for stroke risk assessments in patients with AF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 24. doi: 10.1161/CIRCULATIONAHA.124.069440. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Biomarkers reflecting brain injury are not routinely used in risk assessment of stroke in atrial fibrillation (AF). Neurofilament light chain (NFL) is a novel biomarker released into blood after cerebral insults. We investigated the association between plasma concentrations of NFL, other biomarkers, and risk of stroke and death in patients with AF not receiving oral anticoagulation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: For this observational study, baseline plasma samples were available from 3077 patients with AF randomized to aspirin in ACTIVE A (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events; 2003 to 2008) and AVERROES (Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; 2007 to 2009). Median follow-up was 1.5 years. NFL was analyzed with a Single Molecule Array (Simoa). Associations with outcomes (total stroke or systemic embolism, ischemic stroke, cardiovascular death, and all-cause death) were explored with Cox regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the combined cohort, the median NFL level was 16.9 ng/L (interquartile range, 11.1-26.5 ng/L), the median age was 71 years, 58% were men, and 13% had a history of previous stroke. NFL was associated with older age, higher creatinine, lower body mass index, previous stroke, female sex, and diabetes but not cardiac rhythm. Higher NFL was associated with a higher risk of stroke or systemic embolism (n=206) independently of clinical characteristics (hazard ratio, 1.27 [95% CI, 1.10-1.46] per doubling of NFL) and other biomarkers (hazard ratio, 1.18 [95% CI, 1.01-1.37]) and including in patients without previous stroke (hazard ratio, 1.23 [95% CI, 1.02-1.48]). NFL was also independently associated with cardiovascular (n=219) and all-cause (n=311) death. The C index for stroke using only NFL was 0.642, on par with the currently used clinical risk scores. Addition of information on NFL improved discrimination in a model also including clinical information, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and high-sensitivity cardiac troponin T, yielding a C index of 0.727.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: NFL reflects overt and covert episodes of cerebral ischemia and improves risk assessment of stroke and death in patients with AF without oral anticoagulation, including in patients without previous stroke. The combination of NFL with information on age, history of stroke, and other biomarkers should be explored as a future avenue for stroke risk assessments in patients with AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39045686/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39045686</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069440>10.1161/CIRCULATIONAHA.124.069440</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39045686</guid>
<pubDate>Wed, 24 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Julia Aulin</dc:creator>
<dc:creator>Karl Sjölin</dc:creator>
<dc:creator>Johan Lindbäck</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>Ziad Hijazi</dc:creator>
<dc:creator>Kim Kultima</dc:creator>
<dc:creator>Jonas Oldgren</dc:creator>
<dc:creator>Lars Wallentin</dc:creator>
<dc:creator>Joachim Burman</dc:creator>
<dc:creator>ACTIVE A and AVERROES Investigators</dc:creator>
<dc:date>2024-07-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39045686</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069440</dc:identifier>
</item>
<item>
<title>Innate immune memory after brain injury drives inflammatory cardiac dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39043180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>The medical burden of stroke extends beyond the brain injury itself and is largely determined by chronic comorbidities that develop secondarily. We hypothesized that these comorbidities might share a common immunological cause, yet chronic effects post-stroke on systemic immunity are underexplored. Here, we identify myeloid innate immune memory as a cause of remote organ dysfunction after stroke. Single-cell sequencing revealed persistent pro-inflammatory changes in monocytes/macrophages in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 12:S0092-8674(24)00702-5. doi: 10.1016/j.cell.2024.06.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The medical burden of stroke extends beyond the brain injury itself and is largely determined by chronic comorbidities that develop secondarily. We hypothesized that these comorbidities might share a common immunological cause, yet chronic effects post-stroke on systemic immunity are underexplored. Here, we identify myeloid innate immune memory as a cause of remote organ dysfunction after stroke. Single-cell sequencing revealed persistent pro-inflammatory changes in monocytes/macrophages in multiple organs up to 3 months after brain injury, notably in the heart, leading to cardiac fibrosis and dysfunction in both mice and stroke patients. IL-1β was identified as a key driver of epigenetic changes in innate immune memory. These changes could be transplanted to naive mice, inducing cardiac dysfunction. By neutralizing post-stroke IL-1β or blocking pro-inflammatory monocyte trafficking with a CCR2/5 inhibitor, we prevented post-stroke cardiac dysfunction. Such immune-targeted therapies could potentially prevent various IL-1β-mediated comorbidities, offering a framework for secondary prevention immunotherapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39043180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39043180</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.028>10.1016/j.cell.2024.06.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39043180</guid>
<pubDate>Tue, 23 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Alba Simats</dc:creator>
<dc:creator>Sijia Zhang</dc:creator>
<dc:creator>Denise Messerer</dc:creator>
<dc:creator>Faye Chong</dc:creator>
<dc:creator>Sude Beşkardeş</dc:creator>
<dc:creator>Aparna Sharma Chivukula</dc:creator>
<dc:creator>Jiayu Cao</dc:creator>
<dc:creator>Simon Besson-Girard</dc:creator>
<dc:creator>Felipe A Montellano</dc:creator>
<dc:creator>Caroline Morbach</dc:creator>
<dc:creator>Olga Carofiglio</dc:creator>
<dc:creator>Alessio Ricci</dc:creator>
<dc:creator>Stefan Roth</dc:creator>
<dc:creator>Gemma Llovera</dc:creator>
<dc:creator>Rashween Singh</dc:creator>
<dc:creator>Yiming Chen</dc:creator>
<dc:creator>Severin Filser</dc:creator>
<dc:creator>Nikolaus Plesnila</dc:creator>
<dc:creator>Christian Braun</dc:creator>
<dc:creator>Hannah Spitzer</dc:creator>
<dc:creator>Ozgun Gokce</dc:creator>
<dc:creator>Martin Dichgans</dc:creator>
<dc:creator>Peter U Heuschmann</dc:creator>
<dc:creator>Kinta Hatakeyama</dc:creator>
<dc:creator>Eduardo Beltrán</dc:creator>
<dc:creator>Sebastian Clauss</dc:creator>
<dc:creator>Boyan Bonev</dc:creator>
<dc:creator>Christian Schulz</dc:creator>
<dc:creator>Arthur Liesz</dc:creator>
<dc:date>2024-07-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Innate immune memory after brain injury drives inflammatory cardiac dysfunction</dc:title>
<dc:identifier>pmid:39043180</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.028</dc:identifier>
</item>
<item>
<title>Presynaptic sensor and silencer of peptidergic transmission reveal neuropeptides as primary transmitters in pontine fear circuit</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39043179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>Neurons produce and release neuropeptides to communicate with one another. Despite their importance in brain function, circuit-based mechanisms of peptidergic transmission are poorly understood, primarily due to the lack of tools for monitoring and manipulating neuropeptide release in vivo. Here, we report the development of two genetically encoded tools for investigating peptidergic transmission in behaving mice: a genetically encoded large dense core vesicle (LDCV) sensor that detects...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 17:S0092-8674(24)00709-8. doi: 10.1016/j.cell.2024.06.035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Neurons produce and release neuropeptides to communicate with one another. Despite their importance in brain function, circuit-based mechanisms of peptidergic transmission are poorly understood, primarily due to the lack of tools for monitoring and manipulating neuropeptide release in vivo. Here, we report the development of two genetically encoded tools for investigating peptidergic transmission in behaving mice: a genetically encoded large dense core vesicle (LDCV) sensor that detects presynaptic neuropeptide release and a genetically encoded silencer that specifically degrades neuropeptides inside LDCVs. Using these tools, we show that neuropeptides, not glutamate, encode the unconditioned stimulus in the parabrachial-to-amygdalar threat pathway during Pavlovian threat learning. We also show that neuropeptides play important roles in encoding positive valence and suppressing conditioned threat response in the amygdala-to-parabrachial endogenous opioidergic circuit. These results show that our sensor and silencer for presynaptic peptidergic transmission are reliable tools to investigate neuropeptidergic systems in awake, behaving animals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39043179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39043179</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.035>10.1016/j.cell.2024.06.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39043179</guid>
<pubDate>Tue, 23 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Dong-Il Kim</dc:creator>
<dc:creator>Sekun Park</dc:creator>
<dc:creator>Seahyung Park</dc:creator>
<dc:creator>Mao Ye</dc:creator>
<dc:creator>Jane Y Chen</dc:creator>
<dc:creator>Sukjae J Kang</dc:creator>
<dc:creator>Jinho Jhang</dc:creator>
<dc:creator>Avery C Hunker</dc:creator>
<dc:creator>Larry S Zweifel</dc:creator>
<dc:creator>Kathleen M Caron</dc:creator>
<dc:creator>Joan M Vaughan</dc:creator>
<dc:creator>Alan Saghatelian</dc:creator>
<dc:creator>Richard D Palmiter</dc:creator>
<dc:creator>Sung Han</dc:creator>
<dc:date>2024-07-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Presynaptic sensor and silencer of peptidergic transmission reveal neuropeptides as primary transmitters in pontine fear circuit</dc:title>
<dc:identifier>pmid:39043179</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.035</dc:identifier>
</item>
<item>
<title>Long-term outcomes of high bleeding risk patients undergoing percutaneous coronary intervention: a Korean nationwide registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39042715/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients undergoing PCI, those with HBR were at increased long-term risk for both bleeding and ischaemic events, with a greater risk of mortality compared to non-HBR patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 23:ehae462. doi: 10.1093/eurheartj/ehae462. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients with high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) are at increased risk of not only bleeding, but also ischaemic events. This study aimed to determine the long-term relative risk of ischaemic and bleeding events in HBR patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study was a nationwide cohort study, based on the Korean National Health Insurance Review and Assessment Service database. Patients diagnosed with stable angina or acute coronary syndrome and those who underwent PCI in Korea between 2009 and 2018 were included in the analysis. According to the Academic Research Consortium HBR criteria, the total population was divided into HBR and non-HBR groups. The co-primary outcomes were major bleeding events and ischaemic (composite of cardiac death, myocardial infarction, and ischaemic stroke) events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among a total of 325 417 patients who underwent PCI, 66 426 patients (20.4%) had HBR. During the follow-up period, HBR patients had a higher risk for major bleeding events (23.9% vs. 8.9%, P &lt; .001) and ischaemic events (33.8% vs. 14.4%, P &lt; .001). However, the impact of HBR was significant for major bleeding events [hazard ratio (HR) 3.12, 95% confidence interval (CI) 3.04-3.21, P &lt; .001] and for ischaemic events (HR 2.50, 95% CI 2.45-2.56, P &lt; .001). The HBR group was also associated with a greater risk of all-cause mortality (HR 3.73, 95% CI 3.66-3.79, P &lt; .001). The average annual rate of major bleeding events within the first year after PCI was 5.5% for a single major criterion, and 2.9% for a single minor criterion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients undergoing PCI, those with HBR were at increased long-term risk for both bleeding and ischaemic events, with a greater risk of mortality compared to non-HBR patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39042715/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39042715</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae462>10.1093/eurheartj/ehae462</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39042715</guid>
<pubDate>Tue, 23 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeehoon Kang</dc:creator>
<dc:creator>Junpil Yun</dc:creator>
<dc:creator>Kyung Woo Park</dc:creator>
<dc:creator>Minae Park</dc:creator>
<dc:creator>Sojeong Park</dc:creator>
<dc:creator>Doyeon Hwang</dc:creator>
<dc:creator>Jung-Kyu Han</dc:creator>
<dc:creator>Han-Mo Yang</dc:creator>
<dc:creator>Hyun-Jae Kang</dc:creator>
<dc:creator>Bon-Kwon Koo</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Philip Urban</dc:creator>
<dc:creator>Hyo-Soo Kim</dc:creator>
<dc:date>2024-07-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long-term outcomes of high bleeding risk patients undergoing percutaneous coronary intervention: a Korean nationwide registry</dc:title>
<dc:identifier>pmid:39042715</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae462</dc:identifier>
</item>
<item>
<title>SGLT2 Inhibitors Act Independently of &lt;em>;SGLT2&lt;/em>; to Confer Benefit for HFrEF in Mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39041214/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 23. doi: 10.1161/CIRCRESAHA.124.324823. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39041214/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39041214</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324823>10.1161/CIRCRESAHA.124.324823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39041214</guid>
<pubDate>Tue, 23 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Justin H Berger</dc:creator>
<dc:creator>Timothy R Matsuura</dc:creator>
<dc:creator>Caitlyn E Bowman</dc:creator>
<dc:creator>Renee Taing</dc:creator>
<dc:creator>Jiten Patel</dc:creator>
<dc:creator>Ling Lai</dc:creator>
<dc:creator>Teresa C Leone</dc:creator>
<dc:creator>Jeffrey D Reagan</dc:creator>
<dc:creator>Saptarsi M Haldar</dc:creator>
<dc:creator>Zoltan Arany</dc:creator>
<dc:creator>Daniel P Kelly</dc:creator>
<dc:date>2024-07-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>SGLT2 Inhibitors Act Independently of &lt;em>;SGLT2&lt;/em>; to Confer Benefit for HFrEF in Mice</dc:title>
<dc:identifier>pmid:39041214</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324823</dc:identifier>
</item>
<item>
<title>'Caterpillar-like' pseudoaneurysms in Behçet's disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39041184/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 23:ehae448. doi: 10.1093/eurheartj/ehae448. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39041184/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39041184</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae448>10.1093/eurheartj/ehae448</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39041184</guid>
<pubDate>Tue, 23 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jinting Ge</dc:creator>
<dc:creator>Tiehao Wang</dc:creator>
<dc:creator>Ding Yuan</dc:creator>
<dc:date>2024-07-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>'Caterpillar-like' pseudoaneurysms in Behçet's disease</dc:title>
<dc:identifier>pmid:39041184</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae448</dc:identifier>
</item>
<item>
<title>Cardiac sarcomere turnover by unidirectional replacement of proteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39039179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 22. doi: 10.1038/s41569-024-01065-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39039179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39039179</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01065-3>10.1038/s41569-024-01065-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39039179</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cardiac sarcomere turnover by unidirectional replacement of proteins</dc:title>
<dc:identifier>pmid:39039179</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01065-3</dc:identifier>
</item>
<item>
<title>Standardization and clinical applications of retinal imaging biomarkers for cardiovascular disease: a Roadmap from an NHLBI workshop</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39039178/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>The accessibility of the retina with the use of non-invasive and relatively low-cost ophthalmic imaging techniques and analytics provides a unique opportunity to improve the detection, diagnosis and monitoring of systemic diseases. The National Heart, Lung, and Blood Institute conducted a workshop in October 2022 to examine this concept. On the basis of the discussions at that workshop, this Roadmap describes current knowledge gaps and new research opportunities to evaluate the relationships...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 22. doi: 10.1038/s41569-024-01060-8. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The accessibility of the retina with the use of non-invasive and relatively low-cost ophthalmic imaging techniques and analytics provides a unique opportunity to improve the detection, diagnosis and monitoring of systemic diseases. The National Heart, Lung, and Blood Institute conducted a workshop in October 2022 to examine this concept. On the basis of the discussions at that workshop, this Roadmap describes current knowledge gaps and new research opportunities to evaluate the relationships between the eye (in particular, retinal biomarkers) and the risk of cardiovascular diseases, including coronary artery disease, heart failure, stroke, hypertension and vascular dementia. Identified gaps include the need to simplify and standardize the capture of high-quality images of the eye by non-ophthalmic health workers and to conduct longitudinal studies using multidisciplinary networks of diverse at-risk populations with improved implementation and methods to protect participant and dataset privacy. Other gaps include improving the measurement of structural and functional retinal biomarkers, determining the relationship between microvascular and macrovascular risk factors, improving multimodal imaging 'pipelines', and integrating advanced imaging with 'omics', lifestyle factors, primary care data and radiological reports, by using artificial intelligence technology to improve the identification of individual-level risk. Future research on retinal microvascular disease and retinal biomarkers might additionally provide insights into the temporal development of microvascular disease across other systemic vascular beds.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39039178/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39039178</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01060-8>10.1038/s41569-024-01060-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39039178</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Emily Y Chew</dc:creator>
<dc:creator>Stephen A Burns</dc:creator>
<dc:creator>Alison G Abraham</dc:creator>
<dc:creator>Mathieu F Bakhoum</dc:creator>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:creator>Toco Y P Chui</dc:creator>
<dc:creator>Robert P Finger</dc:creator>
<dc:creator>Alejandro F Frangi</dc:creator>
<dc:creator>Rebecca F Gottesman</dc:creator>
<dc:creator>Maria B Grant</dc:creator>
<dc:creator>Henner Hanssen</dc:creator>
<dc:creator>Cecilia S Lee</dc:creator>
<dc:creator>Michelle L Meyer</dc:creator>
<dc:creator>Damiano Rizzoni</dc:creator>
<dc:creator>Alicja R Rudnicka</dc:creator>
<dc:creator>Joel S Schuman</dc:creator>
<dc:creator>Sara B Seidelmann</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Bishow B Adhikari</dc:creator>
<dc:creator>Narasimhan Danthi</dc:creator>
<dc:creator>Yuling Hong</dc:creator>
<dc:creator>Diane Reid</dc:creator>
<dc:creator>Grace L Shen</dc:creator>
<dc:creator>Young S Oh</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Standardization and clinical applications of retinal imaging biomarkers for cardiovascular disease: a Roadmap from an NHLBI workshop</dc:title>
<dc:identifier>pmid:39039178</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01060-8</dc:identifier>
</item>
<item>
<title>RNA Editing Holds Promise for Hypertrophic Cardiomyopathy Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038091/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):299-301. doi: 10.1161/CIRCULATIONAHA.124.070137. Epub 2024 Jul 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038091/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39038091</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070137>10.1161/CIRCULATIONAHA.124.070137</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038091</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lucie Carrier</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>RNA Editing Holds Promise for Hypertrophic Cardiomyopathy Therapy</dc:title>
<dc:identifier>pmid:39038091</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070137</dc:identifier>
</item>
<item>
<title>Misdiagnosis From a Smart Watch</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038090/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):340-342. doi: 10.1161/CIRCULATIONAHA.124.068979. Epub 2024 Jul 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038090/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39038090</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068979>10.1161/CIRCULATIONAHA.124.068979</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038090</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yaanik B Desai</dc:creator>
<dc:creator>Nitish Badhwar</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Misdiagnosis From a Smart Watch</dc:title>
<dc:identifier>pmid:39038090</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068979</dc:identifier>
</item>
<item>
<title>Illness Trajectories After Revascularization in Patients With Peripheral Artery Disease: A Unified Approach to Understanding the Risk of Major Amputation and Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The illness-death model provides an integrated framework to understand patient outcomes after lower limb revascularization for PAD. Although mortality increased with age, the study highlights patients &lt;60 years of age were at increased risk of major amputation, particularly after nonelective revascularization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):261-271. doi: 10.1161/CIRCULATIONAHA.123.067687. Epub 2024 Jul 22.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The aim of this study was to investigate the illness trajectories of patients with peripheral artery disease (PAD) after revascularization and estimate the independent risks of major amputation and death (from any cause) and their interaction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from Hospital Episode Statistics Admitted Patient Care were used to identify patients (≥50 years of age) who underwent lower limb revascularization for PAD in England from April 2013 to March 2020. A Markov illness-death model was developed to describe patterns of survival after the initial lower limb revascularization, if and when patients experienced major amputation, and survival after amputation. The model was also used to investigate the association between patient characteristics and these illness trajectories. We also analyzed the relative contribution of deaths after amputation to overall mortality and how the risk of mortality after amputation was related to the time from the index revascularization to amputation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study analyzed 94 690 patients undergoing lower limb revascularization for PAD from 2013 to 2020. The majority were men (65.6%), and the median age was 72 years (interquartile range, 64-79). One-third (34.8%) of patients had nonelective revascularization, whereas others had elective procedures. For nonelective patients, the amputation rate was 15.2% (95% CI, 14.4-16.0) and 19.9% (19.0-20.8) at 1 and 5 years after revascularization, respectively. For elective patients, the corresponding amputation rate was 2.7% (95% CI, 2.4-3.1) and 5.3% (4.9-5.8). Overall, the risk of major amputation was higher among patients who were younger, had tissue loss, diabetes, greater frailty, nonelective revascularization, and more distal procedures. The mortality rate at 5 years after revascularization was 64.3% (95% CI, 63.2-65.5) for nonelective patients and 33.0% (32.0-34.1) for elective patients. After major amputation, patients were at an increased risk of mortality if they underwent major amputation within 6 months after the index revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The illness-death model provides an integrated framework to understand patient outcomes after lower limb revascularization for PAD. Although mortality increased with age, the study highlights patients &lt;60 years of age were at increased risk of major amputation, particularly after nonelective revascularization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39038089</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067687>10.1161/CIRCULATIONAHA.123.067687</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038089</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Qiuju Li</dc:creator>
<dc:creator>Panagiota Birmpili</dc:creator>
<dc:creator>Eleanor Atkins</dc:creator>
<dc:creator>Amundeep S Johal</dc:creator>
<dc:creator>Sam Waton</dc:creator>
<dc:creator>Robin Williams</dc:creator>
<dc:creator>Jonathan R Boyle</dc:creator>
<dc:creator>Denis W Harkin</dc:creator>
<dc:creator>Arun D Pherwani</dc:creator>
<dc:creator>David A Cromwell</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Illness Trajectories After Revascularization in Patients With Peripheral Artery Disease: A Unified Approach to Understanding the Risk of Major Amputation and Death</dc:title>
<dc:identifier>pmid:39038089</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067687</dc:identifier>
</item>
<item>
<title>Global Collaborative Cardiovascular Research: The Collective Wisdom of Countries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038088/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):258-260. doi: 10.1161/CIRCULATIONAHA.124.068235. Epub 2024 Jul 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038088/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39038088</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068235>10.1161/CIRCULATIONAHA.124.068235</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038088</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Paul W Armstrong</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Global Collaborative Cardiovascular Research: The Collective Wisdom of Countries</dc:title>
<dc:identifier>pmid:39038088</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068235</dc:identifier>
</item>
<item>
<title>Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most frequently implemented in ACS patients undergoing percutaneous coronary intervention (PCI) across the globe. Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events)...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):317-335. doi: 10.1161/CIRCULATIONAHA.124.069012. Epub 2024 Jul 22.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most frequently implemented in ACS patients undergoing percutaneous coronary intervention (PCI) across the globe. Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, which, by design, studied DAPT versus no DAPT rather than the optimal DAPT duration. The average DAPT duration in this study was 9 months, not 12 months. Subsequent ACS studies, which were not designed to assess DAPT duration, rather its composition (aspirin with prasugrel or ticagrelor compared with clopidogrel) were further interpreted as supportive evidence for 12-month DAPT duration. In these studies, the median DAPT duration was 9 or 15 months for ticagrelor and prasugrel, respectively. Several subsequent studies questioned the 12-month regimen and suggested that DAPT duration should either be fewer than 12 months in patients at high bleeding risk or more than 12 months in patients at high ischemic risk who can safely tolerate the treatment. Bleeding, rather than ischemic risk assessment, has emerged as a treatment modifier for maximizing the net clinical benefit of DAPT, due to excessive bleeding and no clear benefit of prolonged treatment regimens in high bleeding risk patients. Multiple DAPT de-escalation treatment strategies, including switching from prasugrel or ticagrelor to clopidogrel, reducing the dose of prasugrel or ticagrelor, and shortening DAPT duration while maintaining monotherapy with ticagrelor, have been consistently shown to reduce bleeding without increasing fatal or nonfatal cardiovascular or cerebral ischemic risks compared with 12-month DAPT. However, 12-month DAPT remains the only class-I DAPT recommendation for patients with ACS despite the lack of prospectively established evidence, leading to unnecessary and potentially harmful overtreatment in many patients. It is time for clinical practice and guideline recommendations to be updated to reflect the totality of the evidence regarding the optimal DAPT duration in ACS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39038086</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069012>10.1161/CIRCULATIONAHA.124.069012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038086</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Antonio Landi</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Usman Baber</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Shamir R Mehta</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:creator>Dirk Sibbing</dc:creator>
<dc:creator>P Gabriel Steg</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Robert F Storey</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome</dc:title>
<dc:identifier>pmid:39038086</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069012</dc:identifier>
</item>
<item>
<title>Biological and Procedural Predictors of Outcome in the Stroke Preclinical Assessment Network (SPAN) Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39034919/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our analyses identified variables affecting endovascular filament MCAo outcome, an experimental stroke model used worldwide. Multiple regression refuted some commonly reported predictors and revealed previously unrecognized associations. Given the multicenter prospective design that represents a sampling of real-world conditions, the degree of heterogeneity mimicking clinical trials, the large number of predictors adjusted for in the multivariable model, and the large sample size,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 22. doi: 10.1161/CIRCRESAHA.123.324139. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The SPAN trial (Stroke Preclinical Assessment Network) is the largest preclinical study testing acute stroke interventions in experimental focal cerebral ischemia using endovascular filament middle cerebral artery occlusion (MCAo). Besides testing interventions against controls, the prospective design captured numerous biological and procedural variables, highlighting the enormous heterogeneity introduced by the multicenter structure that might influence stroke outcomes. Here, we leveraged the unprecedented sample size achieved by the SPAN trial and the prospective design to identify the biological and procedural variables that affect experimental stroke outcomes in transient endovascular filament MCAo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study cohort included all mice enrolled and randomized in the SPAN trial (N=1789). Mice were subjected to 60-minute MCAo and followed for a month. Thirteen biological and procedural independent variables and 4 functional (weight loss and 4-point neuroscore on days 1 and 2, corner test on days 7 and 28, and mortality) and 3 tissue (day 2, magnetic resonance imaging infarct volumes and swelling; day 30, magnetic resonance imaging tissue loss) outcome variables were prospectively captured. Multivariable regression with stepwise elimination was used to identify the predictors and their effect sizes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Older age, active circadian stage at MCAo, and thinner and longer filament silicone tips predicted higher mortality. Older age, larger body weight, longer anesthesia duration, and longer filament tips predicted worse neuroscores, while high-fat diet and blood flow monitoring predicted milder neuroscores. Older age and a high-fat diet predicted worse corner test performance. While shorter filament tips predicted more ipsiversive turning, longer filament tips appeared to predict contraversive turning. Age, sex, and weight interacted when predicting the infarct volume. Older age was associated with smaller infarcts on day 2 magnetic resonance imaging, especially in animals with larger body weights; this association was most conspicuous in females. High-fat diet also predicted smaller infarcts. In contrast, the use of cerebral blood flow monitoring and more severe cerebral blood flow drop during MCAo, longer anesthesia, and longer filament tips all predicted larger infarcts. Bivariate analyses among the dependent variables highlighted a disconnect between tissue and functional outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our analyses identified variables affecting endovascular filament MCAo outcome, an experimental stroke model used worldwide. Multiple regression refuted some commonly reported predictors and revealed previously unrecognized associations. Given the multicenter prospective design that represents a sampling of real-world conditions, the degree of heterogeneity mimicking clinical trials, the large number of predictors adjusted for in the multivariable model, and the large sample size, we think this is the most definitive analysis of the predictors of preclinical stroke outcome to date. Future multicenter experimental stroke trials should standardize or at least ensure a balanced representation of the biological and procedural variables identified herein as potential confounders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39034919/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39034919</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324139>10.1161/CIRCRESAHA.123.324139</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39034919</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Andreia Morais</dc:creator>
<dc:creator>Takahiko Imai</dc:creator>
<dc:creator>Xuyan Jin</dc:creator>
<dc:creator>Joseph J Locascio</dc:creator>
<dc:creator>Ligia Boisserand</dc:creator>
<dc:creator>Alison L Herman</dc:creator>
<dc:creator>Anjali Chauhan</dc:creator>
<dc:creator>Jessica Lamb</dc:creator>
<dc:creator>Karisma Nagarkatti</dc:creator>
<dc:creator>Marcio A Diniz</dc:creator>
<dc:creator>Mariia Kumskova</dc:creator>
<dc:creator>Nirav Dhanesha</dc:creator>
<dc:creator>Pradip K Kamat</dc:creator>
<dc:creator>Mohammad Badruzzaman Khan</dc:creator>
<dc:creator>Krishnan M Dhandapani</dc:creator>
<dc:creator>Rakesh B Patel</dc:creator>
<dc:creator>Brijesh Sutariya</dc:creator>
<dc:creator>Yanrong Shi</dc:creator>
<dc:creator>Klaus van Leyen</dc:creator>
<dc:creator>W Taylor Kimberly</dc:creator>
<dc:creator>David C Hess</dc:creator>
<dc:creator>Jaroslaw Aronowski</dc:creator>
<dc:creator>Enrique C Leira</dc:creator>
<dc:creator>Raymond C Koehler</dc:creator>
<dc:creator>Anil K Chauhan</dc:creator>
<dc:creator>Lauren H Sansing</dc:creator>
<dc:creator>Patrick D Lyden</dc:creator>
<dc:creator>Cenk Ayata</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Biological and Procedural Predictors of Outcome in the Stroke Preclinical Assessment Network (SPAN) Trial</dc:title>
<dc:identifier>pmid:39034919</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324139</dc:identifier>
</item>
<item>
<title>Discovery of deaminase functions by structure-based protein clustering</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39033754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 20:S0092-8674(24)00718-9. doi: 10.1016/j.cell.2024.07.003. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39033754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39033754</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.003>10.1016/j.cell.2024.07.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39033754</guid>
<pubDate>Sun, 21 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiaying Huang</dc:creator>
<dc:creator>Qiupeng Lin</dc:creator>
<dc:creator>Hongyuan Fei</dc:creator>
<dc:creator>Zixin He</dc:creator>
<dc:creator>Hu Xu</dc:creator>
<dc:creator>Yunjia Li</dc:creator>
<dc:creator>Kunli Qu</dc:creator>
<dc:creator>Peng Han</dc:creator>
<dc:creator>Qiang Gao</dc:creator>
<dc:creator>Boshu Li</dc:creator>
<dc:creator>Guanwen Liu</dc:creator>
<dc:creator>Lixiao Zhang</dc:creator>
<dc:creator>Jiacheng Hu</dc:creator>
<dc:creator>Rui Zhang</dc:creator>
<dc:creator>Erwei Zuo</dc:creator>
<dc:creator>Yonglun Luo</dc:creator>
<dc:creator>Yidong Ran</dc:creator>
<dc:creator>Jin-Long Qiu</dc:creator>
<dc:creator>Kevin Tianmeng Zhao</dc:creator>
<dc:creator>Caixia Gao</dc:creator>
<dc:date>2024-07-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Discovery of deaminase functions by structure-based protein clustering</dc:title>
<dc:identifier>pmid:39033754</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.003</dc:identifier>
</item>
<item>
<title>Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39032925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240725222950&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 21;45(28):2463-2467. doi: 10.1093/eurheartj/ehae450.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39032925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240725222950&v=2.18.0.post9+e462414">39032925</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae450>10.1093/eurheartj/ehae450</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39032925</guid>
<pubDate>Sat, 20 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-07-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves</dc:title>
<dc:identifier>pmid:39032925</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae450</dc:identifier>
</item>





























</channel>
</rss>